Progress of chimeric antigen receptor in childhood acute T-lymphoblastic leukemia / 国际儿科学杂志

ABSTRACT

Acute lymphoblastic leukemia(ALL)is the most common malignant tumor in childhood, and T-ALL accounts for 10%~15% of all in children with ALL.Based on the application of MICM classification, risk stratification and multi-drugs intensive therapy, the prognosis of children with T-ALL has been improved, but the overall survival rate and event free survival rate are still less than 70%, and the overall survival rate of relapsed / refractory T-ALL is less than 10%.The treatment of T-ALL in children still faces great challenges.CDl9 targeted chimeric antigen receptor(CAR)modified T cells have shown impressive results in children with refractory B-ALL, with remission rate of 70%~90%.The emergence of CAR-T and CAR modified NK cells(CAR-NK)targeted therapy is expected to improve the prognosis of T-ALL in children.This article reviews the latest progress of CAR-T and CAR-NK in children with T-ALL.